{"id":32833,"date":"2025-07-17T15:09:20","date_gmt":"2025-07-17T09:39:20","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=32833"},"modified":"2025-07-17T15:09:21","modified_gmt":"2025-07-17T09:39:21","slug":"medtech-news-for-medtronic-microport-olympus","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-medtronic-microport-olympus","title":{"rendered":"Medtronic Gains CE Mark for LigaSure\u2122 on Hugo\u2122 Robotic System; J&amp;J Wins FDA Nod for VARIPULSE\u2122 Irrigation Update; DSMB Clears Continuation of Aethlon Medical Clinical Study; MicroPort\u00ae CardioFlow Marks First VitaFlow Liberty\u00ae Implants in South Korea; Olympus Unveils EU-ME3 Ultrasound Processor in U.S.; QuidelOrtho, B\u00dcHLMANN Launch fCAL\u00ae &amp; fPELA\u00ae Turbo Assays on VITROS\u2122"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f1d1aa2704c\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f1d1aa2704c\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-medtronic-microport-olympus\/#Medtronic_Secured_CE_Mark_for_LigaSure%E2%84%A2_Technology_Integration_on_Hugo%E2%84%A2_Robotic-Assisted_Surgery_System_Paving_the_Way_for_the_Future_of_Surgery\" >Medtronic Secured CE Mark for LigaSure\u2122 Technology Integration on Hugo\u2122 Robotic-Assisted Surgery System, Paving the Way for the Future of Surgery&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-medtronic-microport-olympus\/#FDA_Approved_Updated_Irrigation_Rate_for_Johnson_and_Johnsons_VARIPULSE%E2%84%A2_Platform\" >FDA Approved Updated Irrigation Rate for Johnson and Johnson\u2019s VARIPULSE\u2122 Platform<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-medtronic-microport-olympus\/#Aethlon_Medical_Inc_Reported_Favorable_Data_Safety_Monitoring_Board_Review_and_Received_Recommendation_to_Proceed_to_the_Next_Clinical_Trial_Cohort\" >Aethlon Medical, Inc. Reported Favorable Data Safety Monitoring Board Review and Received Recommendation to Proceed to the Next Clinical Trial Cohort&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-medtronic-microport-olympus\/#MicroPort%C2%AE_CardioFlows_VitaFlow_Liberty%C2%AE_Achieved_Successful_First_Commercial_Implantations_in_South_Korea\" >MicroPort\u00ae CardioFlow\u2019s VitaFlow Liberty\u00ae Achieved Successful First Commercial Implantations in South Korea&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-medtronic-microport-olympus\/#Olympus_Introduced_EU-ME3_Ultrasound_Processor_to_US_Market_for_Enhanced_GI_and_Pulmonary_Disease_Detection\" >Olympus Introduced EU-ME3 Ultrasound Processor to U.S. Market for Enhanced GI and Pulmonary Disease Detection&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-medtronic-microport-olympus\/#QuidelOrtho_and_BUHLMANN_Laboratories_AG_Announced_the_Launch_of_the_fCAL%C2%AE_and_fPELA%C2%AE_Turbo_Assays_on_VITROS%E2%84%A2_Systems_as_a_MicroTip_Partnership_Assay_MPA\" >QuidelOrtho and B\u00dcHLMANN Laboratories AG Announced the Launch of the fCAL\u00ae and fPELA\u00ae Turbo Assays on VITROS\u2122 Systems as a MicroTip Partnership Assay (MPA)<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-medtronic-secured-ce-mark-for-ligasure-technology-integration-on-hugo-robotic-assisted-surgery-system-paving-the-way-for-the-future-of-surgery-nbsp\"><span class=\"ez-toc-section\" id=\"Medtronic_Secured_CE_Mark_for_LigaSure%E2%84%A2_Technology_Integration_on_Hugo%E2%84%A2_Robotic-Assisted_Surgery_System_Paving_the_Way_for_the_Future_of_Surgery\"><\/span><strong>Medtronic Secured CE Mark for LigaSure\u2122 Technology Integration on Hugo\u2122 Robotic-Assisted Surgery System, Paving the Way for the Future of Surgery&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On July 15, 2025, Medtronic plc, a global leader in healthcare technology, announced that it received CE Mark approval for its LigaSure\u2122 RAS vessel-sealing technology. This approval enhances the capabilities of the Hugo\u2122 robotic-assisted surgery (RAS) system for use in gynecologic, general, and urologic procedures across Europe.<\/p>\n\n\n\n<p>Marking a significant advancement, the LigaSure\u2122 RAS instrument is the first vessel-sealing device designed specifically for robotic platforms. It ushers in a new chapter for the LigaSure\u2122 technology, which has been used in over 35 million procedures across more than 65 countries over the past 20 years.<\/p>\n\n\n\n<p><em>\u201cToday, with CE Mark for LigaSure\u2122 RAS, Medtronic is fulfilling a promise to customers to integrate our trusted vessel-sealing technology onto the Hugo\u2122 RAS system,\u201d said Matt Anderson, senior vice president and president of the Surgical business, which is part of the Medical Surgical Portfolio at Medtronic. \u201cMore than fulfilling a commitment, this regulatory approval is a big step forward as we continue to shape the future of surgery with surgical teams who share our passion and commitment to deliver the best possible care to every patient.\u201d<\/em><\/p>\n\n\n\n<p><em>\u201cLigaSure\u2122 technology is one of the most important advances for minimally invasive surgery because it provides sealing and cutting in a way that is very, very secure for the performance of the surgeon and the security of the patient,\u201d said Dr. Caceres. \u201cAs a robotic surgeon, we want LigaSure\u2122 technology because it gives us confidence in the security of the seal. We are already seeing the benefits in our cases with the Hugo\u2122 RAS system.\u201d<\/em><\/p>\n\n\n\n<p>Exclusively compatible with the Hugo\u2122 RAS system and powered by the Valleylab\u2122 FT10 energy platform, the LigaSure\u2122 RAS Maryland instrument is designed to seal and cut vessels, lymphatics, and thick tissue up to 7 mm in diameter. It delivers consistent vessel sealing in roughly two seconds while reducing thermal spread to surrounding tissues.<\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/surgical-robotic-system-market\"><strong>Surgical Robotic System Market Report<\/strong><\/a>\u201d, the surgical robotic systems market was valued at <strong>USD 11,082.32 million<\/strong> in 2024, growing at a <strong>CAGR of 13.21% <\/strong>during the forecast period from 2025 to 2032 to reach <strong>USD 29,785.13 million<\/strong> by 2032. The rising incidence of chronic disorders such as cancer, cardiovascular diseases, and orthopedic conditions is significantly boosting the demand for advanced surgical interventions, thereby propelling the growth of the surgical robotic systems market. As chronic conditions often require complex, high-precision surgeries, robotic-assisted procedures offer enhanced accuracy, minimal invasiveness, and quicker recovery times, making them highly suitable for treating such ailments. Simultaneously, the increasing number of surgical procedures globally, driven by a growing aging population and a higher prevalence of lifestyle-related health issues, is further escalating the need for efficient and precise surgical tools. In response, key market players are heavily investing in product development activities, focusing on innovations such as compact robotic platforms, AI integration, and enhanced visualization systems. These advancements not only expand the scope of robotic surgery across specialties but also improve surgical outcomes, thereby contributing to the growth of the surgical robotic systems market during the forecast period from 2025 to 2032.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approved-updated-irrigation-rate-for-johnson-and-johnson-s-varipulse-platform\"><span class=\"ez-toc-section\" id=\"FDA_Approved_Updated_Irrigation_Rate_for_Johnson_and_Johnsons_VARIPULSE%E2%84%A2_Platform\"><\/span><strong>FDA Approved Updated Irrigation Rate for Johnson and Johnson\u2019s VARIPULSE\u2122 Platform<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On July 14, 2025, Johnson &amp; Johnson MedTech, a global leader in the treatment of cardiac arrhythmias, received approval from the U.S. Food and Drug Administration (FDA) for an update to the irrigation flow rate of its VARIPULSE\u2122 Platform. This approval underscores the company\u2019s ongoing commitment to advancing pulsed field ablation (PFA) technology in line with real-world clinical practices.<\/p>\n\n\n\n<p>This regulatory milestone comes as Johnson &amp; Johnson MedTech surpasses 10,000 VARIPULSE\u2122 procedures performed across the United States, Europe, Canada, Japan, Hong Kong, China, South Korea, Taiwan, and Australia. Impressively, the platform maintained a neurovascular adverse event rate of under 0.5%.<\/p>\n\n\n\n<p>The VARIPULSE\u2122 Platform is Johnson &amp; Johnson MedTech\u2019s proprietary pulsed field ablation (PFA) system. It comprises the VARIPULSE\u2122 Catheter, the TRUPULSE\u2122 Generator, and the CARTO\u2122 3 Mapping System equipped with VARIPULSE\u2122 software. The platform is now approved for clinical use in the United States, Europe, Asia Pacific, and Canada.<\/p>\n\n\n\n<p><em>&#8220;By learning from real-world experience and working closely with clinicians, we are continuously enhancing our technologies to improve patient care,\u201d said Michael Bodner, Company Group Chair, Electrophysiology &amp; Neurovascular, Johnson &amp; Johnson MedTech. \u201cThis update to the VARIPULSE\u2122 Platform reflects our ongoing commitment to lead the evolution of PFA through meaningful, data-driven improvements that advance product performance and build procedural confidence.\u201d<\/em><\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/radiofrequency-ablation-devices-market\"><strong>Radiofrequency Ablation Devices Market Report<\/strong><\/a>\u201d, the radiofrequency ablation devices market was valued at<strong> USD 3.64 billion<\/strong> in 2023, growing at a <strong>CAGR of 9.37%<\/strong> during the forecast period from 2024 to 2030 to reach <strong>USD 6.19 billion<\/strong> by 2030. The demand for radiofrequency ablation devices is witnessing growth due to the growing prevalence of chronic diseases such as cardiovascular diseases, cancers, a rising geriatric population, and technological advancements in product development and design improvement.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-aethlon-medical-inc-reported-favorable-data-safety-monitoring-board-review-and-received-recommendation-to-proceed-to-the-next-clinical-trial-cohort-nbsp\"><span class=\"ez-toc-section\" id=\"Aethlon_Medical_Inc_Reported_Favorable_Data_Safety_Monitoring_Board_Review_and_Received_Recommendation_to_Proceed_to_the_Next_Clinical_Trial_Cohort\"><\/span><strong>Aethlon Medical, Inc. Reported Favorable Data Safety Monitoring Board Review and Received Recommendation to Proceed to the Next Clinical Trial Cohort&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On July 15, 2025, Aethlon Medical, Inc., a clinical-stage biotechnology company focused on developing its investigational Hemopurifier\u00ae, an extracorporeal therapeutic device for oncology and other indications, announced that the independent Data Safety Monitoring Board (DSMB) overseeing its ongoing clinical trial completed its scheduled safety assessment. Following this review, the DSMB recommended proceeding to the next patient cohort without any protocol modifications.<\/p>\n\n\n\n<p>The ongoing study, titled \u201cSafety, Feasibility, and Dose-Finding Study of Aethlon Hemopurifier in Patients with Solid Tumors Who Stable or Progressive Disease While on a Treatment That Includes Pembrolizumab or Nivolumab,\u201d is designed to evaluate the safety, feasibility, and optimal dosing of the Hemopurifier in a specific patient population.<\/p>\n\n\n\n<p>The DSMB, comprising independent experts in nephrology and oncology, reviewed data from the initial cohort of three patients, each of whom underwent a single 4-hour Hemopurifier session. Their evaluation identified no safety concerns, reaffirming the device\u2019s favorable safety and tolerability profile. Notably, no serious adverse events (SAEs) or dose-limiting toxicities (DLTs) related to the Hemopurifier have been observed to date.<\/p>\n\n\n\n<p>With Cohort 1 completed, enrollment is now open for Cohort 2. Participants in this next phase will receive two Hemopurifier treatments over one week across the study\u2019s three active clinical sites in Australia. The trial aims to enroll between 9 and 18 patients in total. It focuses on evaluating the device\u2019s safety and dosing feasibility in patients with solid tumors who have either stable or progressive disease while receiving checkpoint inhibitors, Pembrolizumab (Keytruda\u00ae) or Nivolumab (Opdivo\u00ae).<\/p>\n\n\n\n<p>The trial\u2019s primary endpoint is the incidence of adverse events and any clinically significant changes in laboratory safety parameters in patients treated with the Hemopurifier. Secondary objectives include evaluating the number of treatments required to reduce levels of tumor-derived extracellular vesicles (EVs) and whether this reduction enhances the immune system\u2019s natural ability to combat tumor cells. These insights will help shape the design of a future pivotal efficacy and safety study required for Premarket Approval (PMA) by regulatory authorities.<\/p>\n\n\n\n<p>Aethlon Medical remains committed to advancing the Hemopurifier for oncology applications and will continue to share progress updates as the trial moves forward.<\/p>\n\n\n\n<p>The Hemopurifier is an investigational, extracorporeal medical device designed to remove both enveloped viruses and tumor-derived extracellular vesicles (EVs) from a patient\u2019s bloodstream. It functions in conjunction with a blood pump and utilizes plasma separation, size exclusion, and affinity binding through a plant-based lectin resin that targets mannose-rich glycoproteins commonly found on EVs and viruses.<\/p>\n\n\n\n<p>The device was granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for two key indications. Treatment of patients with advanced or metastatic cancer who are unresponsive or intolerant to standard-of-care therapies and treatment of life-threatening viral infections not addressed by currently approved therapies. The Hemopurifier is currently under development under an open Investigational Device Exemption (IDE) for both oncology and antiviral indications.<\/p>\n\n\n\n<p><em>\u201cThe DSMB&#8217;s positive recommendation is encouraging and underscores the favorable safety profile observed to date in patients with cancer,&#8221; according to Steven LaRosa, M.D, Chief Medical Officer of Aethlon Medical. &#8220;This marks a significant step forward in the clinical development program for the Hemopurifier in Oncology and brings the company closer to potentially addressing the significant unmet medical need for the approximately 60-70% of patients with cancer who do not experience a lasting clinical response to anti-PD-1 immunotherapy.\u201d<\/em><\/p>\n\n\n\n<p>Solid tumor-derived EVs are believed to contribute to cancer progression, metastasis, and resistance to both immunotherapy and chemotherapy. The Hemopurifier\u2019s ability to selectively remove these vesicles has been demonstrated in both in vitro studies and human clinical settings.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/cancer-therapy-market\"><strong>Cancer Therapy Market Report<\/strong><\/a>\u201d, the cancer therapy market was valued at <strong>USD 169.39 billion<\/strong> in 2023, growing at a <strong>CAGR of 9.12%<\/strong> during the forecast period from 2024 to 2030, to reach <strong>USD 285.96 billion<\/strong> by 2030. The cancer therapy market is witnessing a positive market growth owing to factors such as the rising prevalence of various cancers, which are contributing to the growing demand for cancer treatment, and the presence of factors like an increasing aging population, wherein age plays a key role in cancer development in certain cancer types, namely breast cancer. Moreover, the growing focus on developing targeted therapies due to advancements in precision medicine to provide a more pronounced therapeutic effect is further driving the cancer therapy market, as new products are gaining regulatory approvals for cancer treatment. Collectively, these factors are expected to collectively propel the growth of the cancer therapy market worldwide during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-microport-cardioflow-s-vitaflow-liberty-achieved-successful-first-commercial-implantations-in-south-korea-nbsp\"><span class=\"ez-toc-section\" id=\"MicroPort%C2%AE_CardioFlows_VitaFlow_Liberty%C2%AE_Achieved_Successful_First_Commercial_Implantations_in_South_Korea\"><\/span><strong>MicroPort\u00ae CardioFlow\u2019s VitaFlow Liberty\u00ae Achieved Successful First Commercial Implantations in South Korea&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On July 14, 2025, MicroPort\u00ae CardioFlow announced the successful completion of the first commercial implantations of its VitaFlow Liberty\u00ae Transcatheter Aortic Valve Implantation (TAVI) system in South Korea. Five procedures were carried out at two prominent cardiovascular centers: Seoul St. Mary\u2019s Hospital (The Catholic University of Korea) and Chonnam National University Hospital.<\/p>\n\n\n\n<p>The implantations were overseen by Professor Junjie Zhang, Vice President of Nanjing First Hospital, and conducted by Dr. Chang Ki Yuk at Seoul St. Mary\u2019s Hospital and Dr. Kim Juhan at Chonnam National University Hospital. Postoperative evaluations indicated positive outcomes, with no significant paravalvular leakage or procedural complications, even in a 90-year-old patient suffering from severe aortic stenosis. Both the proctor and attending physicians expressed strong confidence in the system\u2019s clinical performance.<\/p>\n\n\n\n<p>VitaFlow Liberty\u00ae is an evolution of the original VitaFlow\u00ae system, featuring a hybrid-density self-expanding stent, bovine pericardial leaflets, and a dual-layer PET skirt designed to enhance radial strength, enable precise coaxial deployment, and reduce perivalvular leakage. Additionally, its next-generation delivery system integrates an innovative double-reinforced spiral structure that facilitates fast, stable, and accurate valve deployment and retrieval, along with 360-degree bending capability for improved navigation.<\/p>\n\n\n\n<p><em>\u201cUnder Professor Zhang\u2019s guidance, VitaFlow Liberty\u00ae demonstrated excellent performance and stable deployment.\u201d Said Dr. Chang Ki Yuk.&nbsp;<\/em><\/p>\n\n\n\n<p><em>Dr. Kim Juhan added, \u201cThe system\u2019s precision and stability gave us strong confidence in treating complex cases.\u201d<\/em><\/p>\n\n\n\n<p>The introduction of VitaFlow Liberty\u00ae in South Korea represents a key advancement in MicroPort\u00ae CardioFlow\u2019s international growth. The company remains dedicated to pioneering structural heart innovations and delivering exceptional cardiovascular care to patients around the globe.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/transcatheter-aortic-valve-replacement-market\"><strong>Transcatheter Aortic Valve Replacement\/Implantation Market Report<\/strong><\/a>\u201d, the transcatheter aortic valve devices market was valued at <strong>USD 3.23 billion<\/strong> in 2023, growing at a <strong>CAGR of 15.41%<\/strong> during the forecast period from 2024 to 2030 to reach <strong>USD 7.64 billion<\/strong> by 2030. The demand for transcatheter aortic valve replacement devices is primarily being boosted by the increasing prevalence of aortic stenosis disorder, rise in cardiovascular disorders, increasing demand for TAVR procedures, increasing prevalence of aortic regurgitation and the technological advancements about the transcatheter aortic valve replacement arena which are expected to increase in the product demand thereby contributing in the growth of the transcatheter aortic valve replacement devices market during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-olympus-introduced-eu-me3-ultrasound-processor-to-u-s-market-for-enhanced-gi-and-pulmonary-disease-detection-nbsp\"><span class=\"ez-toc-section\" id=\"Olympus_Introduced_EU-ME3_Ultrasound_Processor_to_US_Market_for_Enhanced_GI_and_Pulmonary_Disease_Detection\"><\/span><strong>Olympus Introduced EU-ME3 Ultrasound Processor to U.S. Market for Enhanced GI and Pulmonary Disease Detection&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On July 16, 2025, Olympus Corporation, a global leader in medical technology dedicated to enhancing health, safety, and quality of life, announced the U.S. launch of its next-generation EU-ME3 Ultrasound Processor. This advanced system integrates both endoscopic and endobronchial ultrasound (EUS\/EBUS) capabilities into a single, compact workstation, delivering imaging performance on par with high-end ultrasound centers.<\/p>\n\n\n\n<p>Designed to support both diagnostic imaging and ultrasound-guided interventions, the EU-ME3 is ideal for hepatobiliary, pancreatic, and pulmonary procedures. With its high-resolution imaging, advanced functionality, and user-friendly design, the EU-ME3 pushes the boundaries of endosonography.<\/p>\n\n\n\n<p>To aid in the detection and characterization of lesions, the processor delivers superior image quality for clear visualization during EUS and EBUS procedures. Incorporating technologies like s-FOCUS and Tissue Harmonic Echo, it enhances resolution, improves signal-to-noise ratio, reduces artifacts, and ensures consistent focus across the entire depth of the field.<\/p>\n\n\n\n<p><em>\u201cAs healthcare facilities look for ways to improve patient outcomes and save costs, we are pleased to offer our customers a versatile, state-of-the-art ultrasound platform for GI and pulmonary applications,\u201d said Richard Reynolds, President of the Medical Systems Group at Olympus Corporation of the Americas. \u201cThe EU-ME3 allows physicians to realize clinical efficacy through premier imaging that supports early detection and diagnosis for patients.\u201d<\/em><\/p>\n\n\n\n<p>Smart configuration settings enable healthcare providers to tailor the system to individual physician preferences and procedural needs. The EU-ME3 also offers forward and backward compatibility with Olympus\u00ae EUS and EBUS endoscopes as well as miniature probes. This adaptability enhances cost-efficiency for healthcare facilities by streamlining resources across multiple specialties.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/ultrasound-devices-market\"><strong>Ultrasound Devices Market Report<\/strong><\/a>,\u201d the ultrasound devices market was valued at <strong>USD 6.76 billion<\/strong> in 2023, growing at a <strong>CAGR of 6.82%<\/strong> during the forecast period from 2024 to 2030 to reach <strong>USD 10.05 billion<\/strong> by 2030. The ultrasound devices market is witnessing positive growth owing to the rising incidence of severe chronic diseases such as cardiovascular, urology, and others, further rapid technological developmental activities, growing awareness for early disease detection, and increasing geriatric population across the globe who are more susceptible to developing chronic disorders, and rising adoption owing to no radiation exposure, thereby contributing to the growth of the ultrasound devices market during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-quidelortho-and-buhlmann-laboratories-ag-announced-the-launch-of-the-fcal-and-fpela-turbo-assays-on-vitros-systems-as-a-microtip-partnership-assay-mpa\"><span class=\"ez-toc-section\" id=\"QuidelOrtho_and_BUHLMANN_Laboratories_AG_Announced_the_Launch_of_the_fCAL%C2%AE_and_fPELA%C2%AE_Turbo_Assays_on_VITROS%E2%84%A2_Systems_as_a_MicroTip_Partnership_Assay_MPA\"><\/span><strong>QuidelOrtho and B\u00dcHLMANN Laboratories AG Announced the Launch of the fCAL\u00ae and fPELA\u00ae Turbo Assays on VITROS\u2122 Systems as a MicroTip Partnership Assay (MPA)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On July 14, 2025, QuidelOrtho Corporation and B\u00dcHLMANN Laboratories AG jointly announced the launch of the B\u00dcHLMANN fCAL turbo and fPELA turbo assays on QuidelOrtho\u2019s VITROS Systems as a MicroTip Partnership Assay (MPA). These particle-enhanced turbidimetric immunoassays offer advanced diagnostic capabilities: the fCAL turbo assay supports the detection of fecal calprotectin, aiding in the diagnosis of inflammatory bowel disease (IBD) and its distinction from irritable bowel syndrome (IBS), while the fPELA turbo assay measures fecal pancreatic elastase, assisting in the identification of pancreatic insufficiency.<\/p>\n\n\n\n<p>This strategic collaboration aligns with key healthcare trends, including the shift toward non-invasive diagnostics, the pursuit of cost-effective solutions, and the increased attention on gastrointestinal and pancreatic health and their broader systemic implications. The fCAL and fPELA turbo assays demonstrate cutting-edge innovation in diagnostics, contributing to the movement toward personalized medicine and preventive healthcare.<\/p>\n\n\n\n<p><em>\u201cThe integration of B\u00dcHLMANN&#8217;s fCAL and fPELA turbo assays with our VITROS Systems represents a significant advancement in IBD and pancreatic insufficiency diagnoses,&#8221; said Jonathan Siegrist, PhD, Executive Vice President of Research &amp; Development &amp; Chief Technology Officer at QuidelOrtho. &#8220;This collaboration allows laboratories to provide fast results to aid in the diagnosis and management of IBD and pancreatic issues. With features like the long calibration interval and the ability to use the CALEX Cap\u2013prepared stool samples directly, we&#8217;re offering a solution that combines clinical accuracy with operational efficiency, ultimately improving patient care.\u201d<\/em><\/p>\n\n\n\n<p><em>&#8220;We are thrilled to collaborate with QuidelOrtho to expand the delivery of an efficient, automated solution for fecal biomarker testing,&#8221; said Christian Eberle, Chief Executive Officer at B\u00dcHLMANN Laboratories AG. &#8220;Our assays, combined with the CALEX Cap stool preparation device, optimize stool extraction efficiency to help maximize stability and yield, resulting in robust fecal calprotectin and pancreatic elastase test results. This collaboration between QuidelOrtho and B\u00dcHLMANN Laboratories AG meets evolving patient and provider needs in the era of personalized medicine and preventive healthcare, offering innovative solutions that align with the industry&#8217;s focus on non-invasive, cost-effective, and patient-centric diagnostic tools.&#8221;<\/em><\/p>\n\n\n\n<p>Both assays are now available for use on QuidelOrtho\u2019s VITROS Systems, including the VITROS XT 7600 and 5600 Integrated Systems, and the VITROS 4600 Chemistry System in both the U.S. and international markets. Key features of the assays include results delivered in under 10 minutes, broad reportable measurement ranges, 90-day on-analyzer reagent stability, seamless integration with VITROS Automation Solutions, and streamlined sample extraction and preparation via CALEX\u00ae Cap technology.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/immunoassay-market\"><strong>Immunoassay Market Report<\/strong><\/a>,&#8221; the Immunoassay market is poised for significant growth, projected to achieve a remarkable <strong>CAGR of 7.53%<\/strong> during the forecast period from 2024 to 2030. The demand for immunoassays is primarily being boosted by the increasing prevalence of chronic disorders such as cancers and lifestyle disorders such as diabetes mellitus, among others. The increase in various oncological disorders, such as breast cancer and prostate cancer, is a key factor influencing the positive growth of the market. Further, the rising awareness among people regarding early disease diagnosis is also contributing to the overall growth of the immunoassay market during the forecast period from 2024 to 2030.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Medtronic Secured CE Mark for LigaSure\u2122 Technology Integration on Hugo\u2122 Robotic-Assisted Surgery System, Paving the Way for the Future of Surgery&nbsp; On July 15, 2025, Medtronic plc, a global leader in healthcare technology, announced that it received CE Mark approval for its LigaSure\u2122 RAS vessel-sealing technology. This approval enhances the capabilities of the Hugo\u2122 robotic-assisted [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":32835,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[140,22233,2753,17021,16975,19997,20747,20530],"industry":[17226],"therapeutic_areas":[17228],"class_list":["post-32833","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-cancer-therapy","tag-immunoassay","tag-medical-device","tag-medical-devices-market","tag-medtech-market","tag-radiofrequency-ablation-devices","tag-surgical-robotic-system-market","tag-ultrasound-devices","industry-medical-devices","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MedTech News | Medtronic, MicroPort, Olympus<\/title>\n<meta name=\"description\" content=\"Medtronic\u2019s LigaSure\u2122 Technology Integration; Johnson &amp; Johnson\u2019s VARIPULSE\u2122 Platform; MicroPort\u00ae CardioFlow\u2019s VitaFlow Liberty\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-medtronic-microport-olympus\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedTech News | Medtronic, MicroPort, Olympus\" \/>\n<meta property=\"og:description\" content=\"Medtronic\u2019s LigaSure\u2122 Technology Integration; Johnson &amp; Johnson\u2019s VARIPULSE\u2122 Platform; MicroPort\u00ae CardioFlow\u2019s VitaFlow Liberty\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-medtronic-microport-olympus\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-17T09:39:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-17T09:39:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/17150912\/medtech-news-for-medtronic-microport-olympus.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MedTech News | Medtronic, MicroPort, Olympus","description":"Medtronic\u2019s LigaSure\u2122 Technology Integration; Johnson & Johnson\u2019s VARIPULSE\u2122 Platform; MicroPort\u00ae CardioFlow\u2019s VitaFlow Liberty","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-medtronic-microport-olympus","og_locale":"en_US","og_type":"article","og_title":"MedTech News | Medtronic, MicroPort, Olympus","og_description":"Medtronic\u2019s LigaSure\u2122 Technology Integration; Johnson & Johnson\u2019s VARIPULSE\u2122 Platform; MicroPort\u00ae CardioFlow\u2019s VitaFlow Liberty","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-medtronic-microport-olympus","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-07-17T09:39:20+00:00","article_modified_time":"2025-07-17T09:39:21+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/17150912\/medtech-news-for-medtronic-microport-olympus.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-medtronic-microport-olympus","url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-medtronic-microport-olympus","name":"MedTech News | Medtronic, MicroPort, Olympus","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-medtronic-microport-olympus#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-medtronic-microport-olympus#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/17150912\/medtech-news-for-medtronic-microport-olympus.png","datePublished":"2025-07-17T09:39:20+00:00","dateModified":"2025-07-17T09:39:21+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Medtronic\u2019s LigaSure\u2122 Technology Integration; Johnson & Johnson\u2019s VARIPULSE\u2122 Platform; MicroPort\u00ae CardioFlow\u2019s VitaFlow Liberty","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-news-for-medtronic-microport-olympus"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-medtronic-microport-olympus#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/17150912\/medtech-news-for-medtronic-microport-olympus.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/17150912\/medtech-news-for-medtronic-microport-olympus.png","width":772,"height":482,"caption":"medtech-news-for-medtronic-microport-olympus"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/17150912\/medtech-news-for-medtronic-microport-olympus-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">cancer therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Immunoassay<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">medical device<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Radiofrequency Ablation Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Surgical Robotic System Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ultrasound Devices<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">cancer therapy<\/span>","<span class=\"advgb-post-tax-term\">Immunoassay<\/span>","<span class=\"advgb-post-tax-term\">medical device<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech Market<\/span>","<span class=\"advgb-post-tax-term\">Radiofrequency Ablation Devices<\/span>","<span class=\"advgb-post-tax-term\">Surgical Robotic System Market<\/span>","<span class=\"advgb-post-tax-term\">Ultrasound Devices<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 10 months ago","modified":"Updated 10 months ago"},"absolute_dates":{"created":"Posted on Jul 17, 2025","modified":"Updated on Jul 17, 2025"},"absolute_dates_time":{"created":"Posted on Jul 17, 2025 3:09 pm","modified":"Updated on Jul 17, 2025 3:09 pm"},"featured_img_caption":"medtech-news-for-medtronic-microport-olympus","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32833","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=32833"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32833\/revisions"}],"predecessor-version":[{"id":32834,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32833\/revisions\/32834"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/32835"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=32833"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=32833"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=32833"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=32833"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=32833"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}